The FTSE 100 was buoyed by shining corporate results from several companies in a busy week for the market, with the blue chip index closing 1.1% higher at 7,428 at close of trading on Friday. US markets enjoyed a boost with Amazon and Apple reporting sales ahead of market expectations and hopes that the US […]

The post FTSE 100 rallies with global equities as investors look past US recession appeared first on UK Investor Magazine.

AstraZeneca shares decreased 1.7% to 10,676.4p in late morning trading on Friday, despite a 48% growth in revenue to $22.2 billion, reflecting expansion in all divisions except for Other Medicines. The pharmaceutical giant announced a 71% surge in operating profit to £1.4 billion, excluding the impact of its Alexion acquisition, exchange rates and additional one-time […]

The post AstraZeneca revenue grows to $22.2bn, raises FY guidance on Covid-19 treatments appeared first on UK Investor Magazine.

Oxford Biomedica shares were up 3% to 468p in late morning trading on Friday after the firm announced it had entered into a three-year Master Services and Development Agreement with AstraZeneca. The Agreement would reportedly facilitate the potential future manufacturing opportunities for the AstraZeneca Covid-19 vaccine. Oxford Biomedica noted the deal represents an expansion of […]

The post Oxford BioMedica agrees 3-year extension to AstraZeneca Covid-19 vaccine deal appeared first on UK Investor Magazine.

AstraZeneca announced it had officially received recommendations for EU approval for its breast cancer treatments Enhertu and Lynparza on Monday. The pharmaceutical giant reported the recommended approval of its Enhertu treatment for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen, and the use of its Lynparza (olaparib) treatment for patients with […]

The post AstraZeneca receives recommendations for EU approvals for two breast cancer treatments appeared first on UK Investor Magazine.

AstraZeneca shares fell 0.3% to 10,522p in early morning trading on Friday, following the group’s reported 60% increase in revenue to $11.3 billion in Q1 2022. The pharmaceutical company attributed its growth to the contribution of the Alexion medicines and multiple Vaszevria contracts, which are set to complete delivery by HY1 2022. “AstraZeneca’s product portfolio’s […]

The post AstraZeneca revenues increase 60%, Covid-19 treatments decline appeared first on UK Investor Magazine.

AstraZeneca shares were up 0.4% to 10,553.6p in early morning trading on Thursday, following the firm’s announcement that its Ultomiris treatment had been approved in the US. The treatment was developed for adults with generalised myasthenia gravis (gMG), and is reportedly the first long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with the […]

The post AstraZeneca treatment Ultomiris approved in US appeared first on UK Investor Magazine.

AstraZeneca shares were down 0.8% to 10,198p in early morning trading on Monday, after the pharmaceutical company’s announcement that its anti-body CTLA4 antibody Tremelimumab treatment had been accepted under priority review for a Biologics License Application (BLA) for US patients. The treatment is currently under review for its effects in combination with human monoclonal antibody […]

The post AstraZeneca treatment Tremelimumab accepted for US priority review appeared first on UK Investor Magazine.

FTSE 100 was trading marginally down on Thursday with mining companies’ underwhelming updates dragging the index down. Mining stocks were the FTSE 100 biggest fallers Thursday after Anglo American and Antofagasta provided updates on a Covid interrupted the first quarter of 2022. Despite broad weakness in mining companies, the FTSE 100 was trading mostly flat as […]

The post FTSE 100 dragged by weaker miners appeared first on UK Investor Magazine.

AstraZeneca acquires rare medicines business Alexion AstraZeneca (LON:AZN) saw its revenues surge during H1 thanks to its development of new medicines and sales of its coronavirus vaccine. The pharmaceutical company made $1.2bn in sales from the vaccine over the six month period ending in June, rising from $275m in Q1. It has been suggested that […]

The post AstraZeneca receives boost from Covid vaccine appeared first on UK Investor Magazine.

The merger will bolster AstraZeneca’s offering of cancer medicines AstraZeneca’s (LON:AZN) £28m bid for rival pharmaceutical company Alexion has been approved by the UK’s competition watchdog and is now expected to close in a week. The merger will bolster AstraZeneca’s offering of cancer medicines, the company confirmed, and became subject to a review by the […]

The post AstraZeneca gets all-clear for £27.5bn Alexion acquisition appeared first on UK Investor Magazine.

AstraZeneca share price up by over 4% AstraZeneca (LON:AZN) earned $275m in revenue in Q1 from its Covid-19 vaccine, which it is not making a profit from, as sales of its cancer drugs and growth in emerging markets allowed the pharmaceutical company to surpass its expectations. The FTSE 100 drugmaker confirmed it revenue grew by […]

The post AstraZeneca makes $275m from sales of vaccines appeared first on UK Investor Magazine.

AstraZeneca share price down as Holland halts jab Following reports that the UK’s medicines regulatory body is considering restricting use of the vaccine in younger people, it has now said no decision has been made on a regulatory action relating to the Oxford/AstraZeneca vaccine. Channel 4 News said yesterday that the Medicines and Healthcare products […]

The post No decision made to restrict AstraZeneca vaccine appeared first on UK Investor Magazine.

DAX up despite concerns of blood clots from Oxford/AstraZeneca vaccine France, Germany, Italy and Spain came together to suspend the Oxford/AstraZeneca Covid-19 vaccine in an effort to protect public confidence, it has been reported today. The number of countries to have suspended or limited use of the jab stands at 16, despite the European Medicines […]

The post European nations pull together to suspend Oxford/AstraZeneca vaccine appeared first on UK Investor Magazine.

Vaccine withdrawn by Denmark, Norway and Iceland as a ‘precaution’ Denmark, Norway and Iceland have halted the Oxford/AstraZeneca vaccine after a Danish women died with blood clots after receiving a jab. The EU medicines agency stated that there is no indication the jab had caused the blood clots. AstraZeneca confirmed in a statement that the […]

The post AstraZeneca shares dive as European countries suspend use of vaccine appeared first on UK Investor Magazine.

AstraZeneca profits double to $3.2bn AstraZeneca, the British maker of one of the coronavirus vaccines, announced its profits doubled to $3.2bn on Thursday on account of strong sales of other medicines.  Q4 earnings more than tripled following a robust performance by its cancer drugs, surpassing the company’s expectations. Drug sales rose by 11% to $7.41bn. […]

The post AstraZeneca share price rises as Q4 earnings surpass expectations appeared first on UK Investor Magazine.

Shares at British-Swedish pharmaceutical firm AstraZeneca (LON:AZN) have climbed nearly 1% after it announced that US regulatory bodies have approved the use of its treatment for patients with previously-treated HER2-positive advanced gastric cancer. In the US, gastric cancer is most frequently diagnosed in the advanced stage, with only around 5% of patients surviving beyond the […]

The post AstraZeneca shares up on cancer drug approval appeared first on UK Investor Magazine.

British pharma blue chip, AstraZeneca (LON:AZN), announced on Monday that it had entered into a definitive agreement to acquire Alexion Pharmaceuticals. The company said that Alexion shareholders will each receive $60 in cash, and 2.1243 AstraZeneca American Depositary Shares for each Alexion share. Based on AZN’s reference average ADR price of $54.14, this implies a […]

The post AstraZeneca shares drop on Alexion acquisition appeared first on UK Investor Magazine.

AstraZeneca (LON:AZN) watched its shares rise on Monday, on news that its Forxiga chronic heart failure treatment has been approved in Japan. The company said that heart failure affects around 64 million people worldwide, with at least half of whom suffering from a reduced ejection fraction (when the left ventricle cannot contract adequately and therefore […]

The post AstraZeneca shares rise on Japanese approval of heart disease treatment appeared first on UK Investor Magazine.

Shock, the third Monday in a row where vaccine news push value stocks higher. Though underwhelming, the AstraZeneca (LON:AZN) vaccine trial results shoved long-suffering air travel, financial and commodities stocks higher, once again. Across the FTSE 100, air travel stocks led the way, with Rolls Royce soaring 7.60%, while IAG bounced around 5.50%. Meanwhile, mining […]

The post Air travel, financial and commodities stocks soar on AstraZeneca vaccine news appeared first on UK Investor Magazine.

Shares at Cambridge-based pharmaceuticals firm AstraZeneca (LON:AZN) have slid over 1% on Monday morning despite the news that their coronavirus vaccine, in collaboration with Oxford University, has proven to be up to 90% effective in interim trial data. Initial results showed the first half dose is able to provide 70% protection against the virus, but […]

The post AstraZeneca share price slides despite positive trial results appeared first on UK Investor Magazine.

Unsure of what to do with themselves after a mixed week, global equities posted relatively modest movements as they responded to a varied bag of news updates on vaccine updates, retail sales and US stimulus. Between Pfizer and Moderna one-upping each-other with positive news, markets have been spurred on since the booming US election week. […]

The post Global equities in mixed minds about vaccine, retail sales and US stimulus appeared first on UK Investor Magazine.

While not moving quite as enthusiastically as they did after previous vaccine updates, Pfizer‘s latest news saw global equities nudge higher on Wednesday. Noticeably muted, though, was the FTSE. Having led the pack in recent vaccine news rallies, the index was weighed the pound rising on renewed Brexit hopes. While the Dow Jones rallied by […]

The post FTSE stunted as pound gains on Brexit hopes appeared first on UK Investor Magazine.

AstraZeneca (LON: AZN) has revealed a rise in sales and revenue for the year to date. The pharma giant said in its latest trading update that sales had grown 9% to $18,879m whilst overall revenue had increased 8% compared to the year previously. Pascal Soriot, the chief executive, commented: “We made encouraging headway in the […]

The post AstraZeneca reports rise in sales & revenue appeared first on UK Investor Magazine.

It’s still an election, twenty new COVID policy measures, and a Christmas dinner away, but its worth trying to anticipate what equities will look like as the clock strikes midnight on New Year’s Eve. And, here are three factors to consider. The Christmas COVID Crunch Despite the police commissioner’s misguided tough guy comments about breaking […]

The post Three reasons why New Year’s Eve may be an eventful time for equities appeared first on UK Investor Magazine.

Around the world, pharmaceutical companies and governments are working at record speed to develop a vaccine for the novel coronavirus. There are currently more than 150 potential vaccines in development, with high hopes that an effective product can be introduced to the market within the next year. The demand for a vaccine has increased since […]

The post AstraZeneca and GlaxoSmithKline – the Covid-19 vaccine frontrunners to watch appeared first on UK Investor Magazine.

Shares at Cambridge-based biopharmaceuticals firm AstraZeneca (LON:AZN) have begun a modest rally on Monday as the company resumes its high-stakes coronavirus vaccine trial. Clinical trials of AstraZeneca’s joint venture with Oxford University were forced to halt last week after it emerged that an anonymous participant had suffered from an alleged “adverse reaction”. A New York […]

The post AstraZeneca shares begin rally as Oxford vaccine trial resumes appeared first on UK Investor Magazine.

Shares at Cambridge-based pharmaceutical firm AstraZeneca (LON:AZN) have slipped 1.55% as its coronavirus vaccine trial is put on hold after a participant suffered a suspected adverse reaction. The firm has suspended all clinical trials of its proposed COVID-19 vaccine – which had been in the final stage of human tests – while it routinely reviews […]

The post AstraZeneca shares slip as vaccine trial put on hold appeared first on UK Investor Magazine.

Cambridge-based pharmaceutical firm AstraZeneca (LON:AZN) has announced the EU approval of Imfinzi as a first-line treatment for adults suffering from extensive-stage small cell lung cancer (ES-SCLC). The drug is to be used alongside standard chemotherapy after positive results from AstraZeneca’s Phase III CASPIAN trial showed that Imfinzi plus chemotherapy demonstrated a “statistically significant and clinically […]

The post AstraZeneca receives EU approval for new lung cancer treatment appeared first on UK Investor Magazine.

British-Swedish pharamaceuticals company AstraZeneca (LON:AZN) saw its share price dip on Tuesday despite having announced that its selumetinib treatment had been granted orphan drug designation (ODD) in Japan, for the treatment of neurofibromatosis 1 (NF1). The announcement comes as trials showed the treatment was effective in reducing tumour volume in paediatric patients with NF1, Today’s […]

The post AstraZeneca shares slip despite new Japan orphan drug designation appeared first on UK Investor Magazine.

British pharmaceutical company AstraZeneca (LON:AZN) has stated that it will begin producing doses of its potential Coronavirus vaccine, while awaiting the results from its new treatment’s trials. Astrazeneca Chief Executive Pascal Soriot, told BBC Radio 4’s Today programme, “We are starting to manufacture this vaccine right now. “And we have to have it ready to […]

The post AstraZeneca pledges to mass produce potential Coronavirus vaccine appeared first on UK Investor Magazine.

Shares in UK-based AstraZeneca (LON:AZN) jumped on Tuesday morning after the drug company said it was to begin testing a treatment for COVID-19. In further promising news, AstraZeneca said it progressed a lung cancer drug trial early due to high efficacy of the drug Tagrisso. The AstraZeneca share price was up over 6% higher in […]

The post AstraZeneca share price jumps as COVID-19 drug testing begins and lung cancer trial yields positive results appeared first on UK Investor Magazine.

AstraZeneca plc (LON:AZN) have announced that it has agreed to sublicense the global rights to Movantik. The deal has been struck with RedHill Biopharma Ltd for $67.5 million – and certainly looks like a shrewd piece of business. Movantik is indicated as a treatment for opioid-induced constipation – and Redhill are set to pay AstraZeneca […]

The post AstraZeneca sublicense Movantik to RedHill Biopharma appeared first on UK Investor Magazine.

AstraZeneca plc (LON:AZN) have told the market they have sold a range of hypertension drugs, and have updated shareholders about the outcome of two drug trials. The FTSE 100 listed pharmaceutical giant today updated shareholders by saying it has sold the commercial rights to its Inderal, Tenormin, Tenoretic, Zestril, and Zestoretic to Basildon-based Atnahs Pharma […]

The post AstraZeneca give double update on Monday including Brilinta outcome appeared first on UK Investor Magazine.

FTSE 250 specialist pharmaceutical company Indivior Plc (LON:INDV) announced on Wednesday that it has released an authorised generic version of its treatment to combat opioid addiction. The treatment has been released in the US market in an attempt to combat the anticipated impact of rival companies launching ‘copycat’ products. The decision to launch the treatment […]

The post Indivior releases new treatment, shares dip with copycat fears appeared first on UK Investor Magazine.

Pharmaceutical giant AstraZeneca (LON:AZN) have announced approval of ‘Orphan Drug Designation’ for their new treatment, for hypereosinophilic syndrome. The news follows last news from the latter portion of 2018 that the pharma juggernaut had developed a series of new cancer treatments, though the company experienced mixed success. AstraZeneca’s new treatment The new treatment for hypereosinophilic […]

The post AstraZeneca treatment for rare disease granted orphan status appeared first on UK Investor Magazine.

AstraZeneca (LON:AZN) sees its share price down as markets start July’s trade, adding to June’s dip, despite announcing the approval of Lynparza and Imfinzi. Shares currently stand at 5,201p after receiving approval from the Japanese Ministry of Health for their new breast and lung cancer treatments. Following AstraZeneca and Merck and Co’s (NYSE:MRK) successful test […]

The post AstraZeneca shares drop after new cancer treatment approval appeared first on UK Investor Magazine.